This work was supported by the National Key Research and Development Program of China(2017YFE0126500);the National Natural Science Foundation of China(81861138013,81501105,31730034);Beijing Advanced Innovation Center for Human Brain Protection,Shenzhen Science Technology and Innovation Commission(JCYJ20170411152419928 and JCYJ20180508152240368);Beijing Municipal Science&Technology Commission(Z151100003915118)to B.L.,W.G.;K.P.Strategic Priority Research Program of Chinese Academy of Science(NO.XDB32030200)to HH.We acknowledge funding from Hållstens forskningsstiftelse,Swedish Research Council,Swedish Brain foundation,Swedish Alzheimer foundation,Margaretha af Ugglas Foundation,Sonja Leikrans donation,China Scholarship Council and H2020-MSCA-ITN-2019#860035(R.J.,M.S.,S.T.,J.W.,B.W.and P.N.).We thank Takaomi Saido and Takashi Saito at RIKEN Center for Brain Science,Japan for providing the App knock-in mice to Department of Neurobiology,Care Sciences and Society,Division of Neurogeriatrics,Karolinska Institutet.We thank Dr.P.Davies(Albert Einstein College of Medicine,Bronx,NY)for antibodies Alz-50,and MC-1,Dr.Jianzhi Wang(Tongji Medical College,Huazhong University&Technology,Wuhan,Hubei)for APP/PS1 mice frozen brain sections,Dr.Chuanzhou Li and Dr.Hao Li(Tongji Medical College,Huazhong University&Technology,Wuhan,Hubei)for P301 mice frozen brain sections,Dr.Mengchao Cui(College of Chemistry,Beijing Normal University,Beijing)for P301 mice paraffin brain sections,and Xaomin Wang(Capital Medical University,Beijing)for 5×FAD mice frozen brain sections.We thank the Imaging Core Facility,the Technology Center for Protein Sciences(Tsinghua University)for assistance on confocal imaging and Imaris software data analysis.We also thank Dr.Yichang Jia(School of Medicine,Tsinghua University,Beijing)for the discussion of gene editing strategy and Dr.Guhan Nagappan for manuscript discussion and editing.CRISPR/Cas9 manipulation was done by a CRO company(Beijing Biocytogen Co.,Ltd).
A major obstacle in Alzheimer’s disease(AD)research is the lack of predictive and translatable animal models that reflect disease progression and drug efficacy.Transgenic mice overexpressing amyloid precursor protein...
Dear Editor, Genetically modified monkey models that exhibit hu- man disease symptoms are versatile tools for studying human disease mechanisms and advancing therapeutic treatments [1]. However, generation of gene-ta...
Targeted integration of transgenes can be achieved by strategies based on homologous recombination (HR), mi- crohomology-mediated end joining (MMEJ) or non-homologous end joining (NHEJ). The more generally used ...
The amyloid precursor protein (APP) has been under intensive study in recent years, mainly due to its critical role in the pathogenesis of Alzheimer's disease (AD). β-Amyloid (Aβ) peptides generated from APP ...